Cyclophilin A (CypA) - KRAS G12D Protein Kit | Molecular Glue Discovery | Amid Biosciences

Amid Biosciences offers Cyclophilin A (CypA) - KRAS G12D Protein Kit to support discovery of novel inhibitors for targeting "undruggable" KRAS mutations (e.g., G12D, G12V) by forming a binary complex with chaperone protein cyclophilin A.

The cyclophilin A - KRAS G12D Protein Kit includes:

• Recombinant biotinylated human G12D KRAS (1-185) Protein – 0.05 mg
• Recombinant biotinylated human wild type KRAS (1-185) Protein – 0.05 mg
• Recombinant human Cyclopilin A (CypA) – 0.1 mg.

Catalog # KR12DCP-301

For decades, the KRAS protein was considered "undruggable" due to its smooth, shallow surface that lacked binding sites for small molecule drugs, making it difficult to target for cancer treatment.

Molecular glues are small molecules that force interactions between KRAS proteins and other cellular proteins, often resulting in degradation or inhibition of oncogenic signaling (1, 2).

Revolution Medicines pioneered a novel class of KRAS inhibitors that utilize Cyclophilin A (CypA) to target previously "undruggable" mutant RAS cancers (1). These inhibitors act as molecular glues, binding to the abundant chaperone protein CypA. This binary complex then binds specifically to active (GTP-bound) mutant RAS, creating a new, stable "tri-complex" that inhibits tumor growth.

This product is for laboratory research use only. 

References.

1. Schulze CJ et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023 Aug 18;381(6659):794-799. doi: 10.1126/science.adg9652. Epub 2023 Aug 17. PMID: 37590355; PMCID: PMC10474815.

2. Deng, J., Shen, S., Huang, L.et al.Small-molecule degraders for oncogenic KRASG12Cand pan-KRAS mutations.Nat Commun(2026). https://doi.org/10.1038/s41467-026-71093-9